CareDx

CareDx

Noninvasive transplant diagnostics and patient monitoring

Overview

CareDx provides noninvasive tests and digital tools to support people who receive organ transplants. It offers kidney transplant services, HLA typing for organ matching, and digital platforms to manage transplant care from pre-transplant diagnostics to post-transplant monitoring. It also collaborates with biopharma companies to speed clinical development through its pharma services. The products work by using noninvasive tests to monitor transplant health and by providing software that helps doctors, patients, and caregivers track appointments, results, and treatment plans. Unlike many competitors, CareDx combines testing, data management, and patient support in one integrated system and works with pharma partners, focusing on the full transplant journey rather than just a single piece. The goal is to improve transplant outcomes and patient experiences by making testing and care easier, more accurate, and more coordinated.

Significant Headcount Growth

About CareDx

Simplify's Rating
Why CareDx is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & Analytics

Enterprise Software

Biotechnology

Healthcare

Company Size

51-200

Company Stage

IPO

Headquarters

Brisbane, California

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • Naveris adds Medicare-covered NavDx and expands CareDx into precision oncology surveillance.
  • Q1 2026 testing services revenue grew 48% to $91 million.
  • AlloSeq Nano shortens HLA and ABO typing to under three hours.

What critics are saying

  • CareDx's Lab Products divestiture weakens transplant workflow control and forfeits kit pull-through.
  • Naveris integration and revenue milestones create execution risk before Q3 2026 closing.
  • Reimbursement pressure on biopsy-sparing monitoring can compress margins and slow repeat-testing adoption.

What makes CareDx unique

  • CareDx dominates transplant diagnostics with AlloSure, AlloMap, HeartCare, and AlloSeq.
  • Its evidence base spans 95 transplant centers and large prospective registries.
  • VANTx links molecular tests, EMRs, and real-world evidence for longitudinal transplant analysis.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$152.8M

Below

Industry Average

Funded Over

8 Rounds

Notable Investors:
Post IPO Debt funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Debt Funding Comparison
Coming Soon

Benefits

Health Insurance

Gym Membership

401(k) Company Match

Employee Stock Purchase Plan

Commuter Benefits

Paid Vacation

Stock Price

Growth & Insights

Headcount

6 month growth

0%

1 year growth

3%

2 year growth

1%

Recently Posted Jobs

Sign up to get curated job recommendations

CareDx is Hiring for 9 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →